Yichao Xu | Pharmacology and Drug Development | Innovative Research Award

Published on by Life Science

Innovative Research Award

Yichao Xu
Affiliation Zhejiang University
Country China
Scopus ID 57195473151
Documents 30
Citations 220
h-index 8
Subject Area Pharmacology and Drug Development
Event World Life Science Awards

Yichao Xu is a researcher affiliated with Zhejiang University in China whose supplied academic profile is associated with pharmacology and drug development. The provided profile lists Scopus Author ID 57195473151 and records 30 documents, 220 citations, and an h-index of 8. These bibliometric indicators offer a quantitative overview of the research activity represented in the supplied Scopus profile. [1]

Abstract

This academic recognition profile presents the supplied research information for Yichao Xu, a researcher affiliated with Zhejiang University, China, and associated with pharmacology and drug development. The provided Scopus profile identifies the researcher through Author ID 57195473151 and lists 30 indexed documents, 220 citations, and an h-index of 8.These bibliometric indicators summarize aspects of indexed scholarly output and citation visibility.  [1]

Keywords

  • Yichao Xu
  • Pharmacology
  • Drug development
  • Zhejiang University
  • Research innovation
  • Pharmaceutical research
  • Drug discovery
  • Scientific research
  • Bibliometric indicators
  • Scopus
  • Innovative Research Award
  • World Life Science Awards

Introduction

Pharmacology examines how substances interact with biological systems, including the mechanisms through which drugs produce their effects. Drug development applies scientific evidence and experimental methods to the discovery, evaluation, and development of potential therapeutic products.[2]

Research Profile

The supplied information identifies Yichao Xu as being affiliated with Zhejiang University in China and associates the research profile with pharmacology and drug development.No specific laboratory, research group, individual research project, or detailed experimental specialization was included in the supplied information. Accordingly, this profile does not attribute particular drug candidates, therapeutic discoveries, clinical outcomes, or research methods to the researcher without supporting evidence.

Research Contributions

Pharmacology and drug development encompass research questions related to drug action, biological targets, therapeutic efficacy, safety, and the evaluation of candidate compounds. Work in these fields may contribute to understanding disease mechanisms, identifying potential therapeutic approaches, and establishing evidence to guide further investigation. [2]

Publications

The supplied profile reports 30 documents under Scopus Author ID 57195473151. [Individual publication titles, publication dates, journal names, co-authors, abstracts, and DOI identifiers were not provided as source information for this article. Therefore, no specific publication is attributed to Yichao Xu here without bibliographic verification.The available records should be reviewed directly to confirm publication details and their relevance to pharmacology and drug development.

Research Impact

The supplied Scopus profile reports 220 citations across 30 documents and an h-index of 8. [1] Citation counts provide one measure of how often indexed publications are cited by other scholarly works. The h-index combines publication output and citation activity by identifying a threshold of publications that have each received at least that number of citations. [3]

Award Suitability

This profile is presented in connection with the Innovative Research Award at the World Life Science Awards. The supplied institutional affiliation, subject-area association, and bibliometric indicators provide background information for considering the research profile within an academic recognition context. [1]

A comprehensive award assessment would require review of the candidate’s verified publications, originality of research, methodological quality, documented contributions to pharmacology or drug development, and supporting evidence of research impact. The information presented here does not by itself establish award selection, final eligibility, or an official award outcome.

Conclusion

Yichao Xu is identified in the supplied academic information as a researcher affiliated with Zhejiang University in China and associated with pharmacology and drug development. The provided Scopus profile lists 30 documents, 220 citations, an h-index of 8, and Author ID 57195473151.  These figures offer a concise bibliometric overview, while further assessment of individual research contributions requires examination of verified publications and supporting evidence. [1]

References

  1. Elsevier. (n.d.). Scopus author details: Yichao Xu, Author ID 57195473151. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57195473151
  2. Direct background subtraction LC-MS/MS assay for human plasma progesterone: Full validation and comparative application. Journal of Chromatography B, 1282, 125221.
    https://doi.org/10.1016/j.jchromb.2026.125221
  3. Physiologically based pharmacokinetic model of brigatinib in healthy volunteers and patients with cancer. CPT: Pharmacometrics & Systems Pharmacology, 15(8), e70302.
    https://doi.org/10.1002/psp4.70302

Sachin Sanap | Pharmacology | Best Researcher Award

Published on by Life Science

Dr. Sachin Sanap | Pharmacology | Best Researcher Award

Sun Pharmaceutical Industries Limited | India

Dr. Sachin N. Sanap, Ph.D., is an accomplished Formulation Scientist with over five years of research and development experience spanning academia and the pharmaceutical industry. His expertise lies in parenteral drug formulation, lyophilization, and regulatory-compliant product development, with a strong focus on improving drug delivery efficiency and stability. Dr. Sanap has made significant scientific contributions, authoring 30 research articles, 16 review papers, one book chapter, and securing one patent. His impactful work has earned him an h-index of 15, i10-index of 27, and over 1,200 citations, reflecting his influence in pharmaceutical formulation science. A recipient of the prestigious AcSIR Best PhD Thesis Award  and multiple honors including the Sun Pharma Spotlight Award, Dr. Sanap’s research emphasizes innovative approaches to ophthalmic, peptide, and injectable formulations. His projects, such as sustained-release ophthalmic systems and polymeric liposomal formulations for keratitis, demonstrate translational relevance in therapeutics. Through interdisciplinary collaborations, he bridges laboratory innovation with industrial application, contributing to Cipla–CDRI technology transfer initiatives. With a passion for advancing drug delivery systems, Dr. Sanap continues to explore scalable, bioavailable, and patient-centered pharmaceutical solutions for global healthcare challenges.

Profiles: Google Scholar | Research Gate | LinkedIn

Featured Publications

Biswas, A., Choudhury, A. D., Agrawal, S., Bisen, A. C., Sanap, S. N., Verma, S. K., & others. Recent insights into the etiopathogenesis of diabetic retinopathy and its management. Journal of Ocular Pharmacology and Therapeutics, 40(1), 13–33.

Sanap, S. N., Bisen, A. C., Kedar, A., Yadav, K. S., Krishna, A., Akhir, A., Chopra, S., & others. Chitosan/HPMC-based mucoadhesive film co-loaded with fluconazole and ofloxacin for management of polymicrobial keratitis. International Journal of Biological Macromolecules, 222, 2785–2795.

Sanap, S. N., Bisen, A. C., Mishra, A., Biswas, A., Agrawal, S., Yadav, K. S., & others. QbD based antifungal drug-loaded ophthalmic liposomal formulation for the management of fungal keratitis: In vitro, ex vivo and in vivo pharmacokinetic studies. Journal of Drug Delivery Science and Technology, 74, 103517.

Sanap, S. N., Mishra, A., Bisen, A. C., Agrawal, S., Biswas, A., Verma, S. K., & others.  Simultaneous determination of fluconazole and ofloxacin in rabbit tear fluid by LC-MS/MS: Application to ocular pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 208, 114463.

Mishra, A., Bano, M., Bisen, A. C., Verma, S., Sanap, S. N., Kishor, R., Shukla, P. K., & others. Topical corneal targeted sustained release amphotericin B liposomal formulation for the treatment of fungal keratitis and its PK–PD evaluation. Journal of Drug Delivery Science and Technology, 60, 101944.

.

Soumia Belouafa | Pharmacology | Best Researcher Award

Published on by Life Science

Prof. Soumia Belouafa | Pharmacology | Best Researcher Award

Faculty Ben M’Sick. University Hassan II Casablanca | Morocco

Prof. Soumia Belouafa, a distinguished Professor of Chemistry at the Faculty of Ben M’Sick, Hassan II University of Casablanca, Morocco, has made notable contributions in the field of biomaterials, materials chemistry, and process engineering. Her research primarily focuses on the controlled synthesis of calcium phosphate biomaterials and the application of Quality-by-Design (QbD) methodologies for reproducible and scalable production. With an impressive portfolio of 26 Scopus-indexed journal publications and 10 additional papers, her scholarly influence is reflected in an h-index of 7 and 188 citation counts across leading research platforms such as Scopus and ResearchGate. Prof. Belouafa has successfully integrated process optimization and statistical control in pilot-scale biomaterial synthesis, enhancing reproducibility and clinical applicability for bone regeneration. Her innovative research extends to sustainable material development, including the valorization of marine by-products and eco-efficient antibacterial dental biomaterials. In addition to her academic publications, she holds three patents, evidencing her commitment to translating laboratory innovations into industrial and environmental applications. Through her interdisciplinary approach combining chemistry, process engineering, and analytical validation, Prof. Belouafa has strengthened the bridge between academic science and industrial biotechnology, positioning herself as a leading figure in advanced biomaterials research and innovation.

Profiles: Scupos | Orcid | Google Scholar 

Featured Publications

Outalb, K., Chaair, H., Digua, K., & Belouafa, S. (2026). Temperature control in an ultrasonic bath: A statistical experimental approach. Journal of Thermal Engineering.

Belouafa, S., Berrada, M., Digua, K., & Chaair, H. (2026, July). Design and scale-up of a synthesis process for antimicrobial oxygenated apatites for biomedical applications. Johnson Matthey Technology Review.

Belouafa, S., Berrada, M., Digua, K., & Chaair, H. (2025, June 30). Kinetic control of oxygenated apatites: Dynamic operation of a pilot-scale precipitation reactor for bone-mimetic biomaterials. Minerals.

Bennari, H., Belouafa, S., & Chaair, H. (2025, June 1). The economic and agricultural significance of Phoenix dactylifera: Challenges and opportunities for sustainable development in Morocco’s date palm sector. Journal of Food Science and Technology (Iran).

Bennari, H., El Omari, S., Habsaoui, A., Chaair, H., & Belouafa, S. (2025, February). Toward ISO/IEC 17025 compliance: Challenges and strategies for a university research laboratory. Accreditation and Quality Assurance.

Arpad Furka | Pharmacology | Pioneering Scientist Distinction

Published on by Life Science

Prof. Arpad Furka | Pharmacology | Pioneering Scientist Distinction

Eotvos Lorand University | Hungary

Arpad Furka, born in 1931 in Criscior, Romania, is a distinguished Hungarian organic chemist renowned as the inventor of combinatorial technology, a breakthrough that revolutionized drug discovery by enabling the simultaneous synthesis and screening of billions of organic compounds. After completing his PhD at the University of Szeged in 1959, he pursued a career spanning decades at Eotvos Lorand University, where he became a full professor in 1972. His pioneering contributions in peptide chemistry and split-pool synthesis have had a profound global impact, influencing pharmaceutical research and biomolecular engineering. Furka’s academic influence is reflected in his h-index of 19, with 53 documents and 1,695 citations, signifying the enduring relevance of his work across disciplines. His collaborations with international institutions and industry partners, such as CHINOIN and AdvancedChemTech in the USA, further extended the application of his research. In recognition of his scientific achievements, he has received numerous honors, including the Leonardo da Vinci Excellence Award, the MTA Academic Award, and the prestigious Szechenyi Prize. As Honorary President of the European Society of Combinatorial Sciences, Furka’s legacy continues to inspire innovation, and his extensive body of publications stands as a testament to his role as a visionary in organic and medicinal chemistry.

Profile: Orcid

Featured Publications

The parallel and combinatorial synthesis and screening in drug discovery

Combinatorial technology revitalized by DNA‐encoding

Relative energy of organic compounds V. structure-energy comparisons